Research Topics
| David S EttingerSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?David S Ettinger
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
J Thorac Oncol 2:160-5. 2007..Studies to evaluate the drug in US and European patients with extensive stage small cell lung cancer are ongoing. Levels of NQ01 will also be determined in these studies...
Emerging profile of cetuximab in non-small cell lung cancerDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 New Orleans Street, Baltimore, MD 21231, United States
Lung Cancer 68:332-7. 2010..Cetuximab does not carry restrictions in use due to safety, and therefore it may be a particularly valuable option for patients who are not eligible for other biologics...- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancerDavid S Ettinger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
J Clin Oncol 28:2598-603. 2010..Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase II study was conducted to confirm safety and activity of amrubicin in the treatment of refractory small-cell lung cancer (SCLC)... - Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II studyDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
J Clin Oncol 23:4991-8. 2005.... - An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studiesDavid S Ettinger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
Semin Oncol 32:S109-10. 2005.... - Update: NCCN small cell and non-small cell lung cancer Clinical Practice GuidelinesDavid Ettinger
Upper Aerodigestive Program, The Sidney Kimmel Comprehensive Cancer Center at John Hopkins School of Medicine, Suite 1100 Harry and Jeanette Weinberg Building, 401 N. Broadway, Baltimore, MD 21231, USA
J Natl Compr Canc Netw 3:S17-21. 2005 - Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?David S Ettinger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
Oncologist 7:226-33. 2002..Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose... - Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancerDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21213 1000, USA
Oncologist 11:358-73. 2006..Both mAbs and TKIs have demonstrated encouraging results as monotherapies and in combination with chemotherapy and radiotherapy. This review provides a critical update on the status of these novel therapeutics... - Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapyJulie R Brahmer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Respirology 12:320-5. 2007..Data are presented to support the standard use of adjuvant therapy in patients with stage II and III disease, as well as data supporting the use of neo-adjuvant therapy in selected patients with non-small cell lung cancer... - Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeMalcolm V Brock
Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
J Thorac Cardiovasc Surg 129:64-72. 2005..Although resection is not the standard of care in treating small cell lung cancer, new platinum drugs and modern staging have allowed the role of surgery to be reevaluated... - Multidisciplinary management of lung cancerAlexander Spira
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA
N Engl J Med 350:379-92. 2004 - Chemotherapy for lung cancer: the state of the art in 2009Michaela J Higgins
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB I, Room 186, Baltimore, MD 21231 1000, USA
Expert Rev Anticancer Ther 9:1365-78. 2009..Novel targeted systemic therapies and the appropriate selection of treatments for patients based on their tumors' molecular phenotypes and histologies will also be reviewed... - Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588)David S Ettinger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room G-88, 1650 Orleans Street, Baltimore, MD, USA
Lung Cancer 37:311-8. 2002.... - Managing the patient with borderline resectable lung cancerAni Balmanoukian
The Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
Oncology (Williston Park) 24:234-41. 2010..Most importantly, the treatment strategy for stage IIIA/IIIB disease should involve a multimodality approach individualized to the patient's disease stage, age, underlying medical conditions, and performance status... - Extensive-stage small-cell lung cancerAlexander Spira
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231 1000, USA
Semin Surg Oncol 21:164-75. 2003..In this review we highlight recent developments in the treatment and management of this malignancy, and discuss future prospects in treatment... - Overview and state of the art in the management of lung cancerDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-1000, USA
Oncology (Williston Park) 18:3-9. 2004..Novel innovative therapies, which could include molecular targeting agents, are needed to treat both NSCLC and SCLC... - Non-small cell lung cancer treatment-related bone marrow toxicitiesDavid S Ettinger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231-1000, USA
Semin Oncol 32:S81-5. 2005..In this setting, the use of hematopoietic growth factors may thus be beneficial... - Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settingsDavid S Ettinger
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 New Orleans Street, Baltimore, MD 21231, USA
Support Care Cancer 17:405-11. 2009..This study investigated physician's attitudes toward the relative importance of chemotherapeutic and antiemetic efficacy in different clinical scenarios... - Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancerHillary A Hahm
The Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA
Clin Cancer Res 8:684-90. 2002..Furthermore, the observed dose-limiting toxicity is unique to DENSPM, thus underscoring the potential for DENSPM to be a suitable agent for chemotherapy in combination with agents possessing different spectrums of toxicities... - The use of chemotherapy in soft-tissue sarcomasAlexander I Spira
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Oncologist 7:348-59. 2002..Finally, we discuss the role of chemotherapy in combination with surgery and radiation in the adjuvant and neoadjuvant settings... - Novel antifolate drugsW Thomas Purcell
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G92, Baltimore, MD 21231 1000, USA
Curr Oncol Rep 5:114-25. 2003..Supplementation with folic acid and vitamin B(12) has been shown to reduce the toxicity of pemetrexed without affecting efficacy and has increased the therapeutic index for this novel agent... - Non-small cell lung cancerDavid S Ettinger
J Natl Compr Canc Netw 6:228-69. 2008 - NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancerDonald A Podoloff
J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology... - Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancerJin S Lee
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 52:362-70. 2002..We conducted this retrospective cohort study to examine its impact on the outcome of patients undergoing combined chemoradiation therapy for the treatment of locally advanced inoperable non-small-cell lung cancer... - Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancerChristian Monnerat
Institut Gustave Roussy, Villejuif, France
Clin Cancer Res 10:5439-46. 2004..0%). CONCLUSIONS: This combination had good tolerance and achieved promising overall survival with extended 1- and 2-year survival rates. This cisplatin-free regimen warrants further evaluation in randomized trials... - Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortiumScott Okuno
Mayo Clinic College of Medicine, 200 First St, Southwest, Medical Oncology, Rochester, MN 55905, USA
J Clin Oncol 23:3069-73. 2005..This study was performed to determine the activity of BMS-247550 in patients with soft tissue sarcomas (STSs) who had not received prior chemotherapy for metastatic disease... - Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12Ritsuko Komaki
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 62:342-50. 2005..The purpose of RTOG 97-12 was to determine the maximum tolerated dose (MTD) of thoracic radiation therapy (RT) with concurrent chemotherapy for patients with limited-stage small-cell lung cancer... - Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705Jeffrey D Bradley
Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
J Clin Oncol 23:3480-7. 2005.... - Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514William G Kraybill
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Clin Oncol 24:619-25. 2006..On the basis of a positive reported single-institution pilot study, the Radiation Therapy Oncology Group initiated phase II trial 9514 to evaluate its neoadjuvant regimen in a multi-institutional Intergroup setting... - Neuroendocrine tumorsOrlo H Clark
Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA
J Natl Compr Canc Netw 4:102-38. 2006 - Soft tissue sarcomaGeorge D Demetri
Dana-Faber/Brigham and Women's Cancer Center, USA
J Natl Compr Canc Netw 5:364-99. 2007 - Non-small cell lung cancer clinical practice guidelines in oncologyDavid S Ettinger
J Natl Compr Canc Netw 4:548-82. 2006 - Small cell lung cancerGregory P Kalemkerian
J Natl Compr Canc Netw 6:294-314. 2008 - AntiemesisDavid S Ettinger
J Natl Compr Canc Netw 5:12-33. 2007 - Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaHoward H Bailey
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Cancer 107:2462-7. 2006.... - Changing face of small-cell lung cancer: real and artifactDavid S Ettinger
J Clin Oncol 24:4526-7. 2006 - Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II TrialPatrick J Loehrer
Indiana University Medical Center, Indianapolis, IN 46202, USA
J Clin Oncol 22:293-9. 2004.... - Small cell lung cancer clinical practice guidelines in oncologyBruce E Johnson
J Natl Compr Canc Netw 4:602-22. 2006